JSM 2012 Online Program

The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.

Online Program Home


473 *	Wed, 8/1/2012, 8:30 AM - 10:20 AM	CC-Room 23A
Innovations in Survival Analysis: PFS and Other Issues — Contributed Papers
Biopharmaceutical Section
Chair(s): Steven Sun, Johnson & Johnson
8:35 AM	On the Translation of a Treatment's Effect on Disease Progression Into an Effect on Overall Survival — Qi Jiang, Amgen, Inc. ; Steven Michael Snapinn, Amgen, Inc.
8:50 AM	Translation of Progression-Free Survival Benefit Into Overall Survival in Cancer Trials — Yiyun Tang, Pfizer Inc. ; Keiji Imai, Pfizer Inc. ; Paul Bycott, Pfizer Inc.
9:05 AM	Estimation of Correlation Between Overall Survival and Surrogate Endpoints — Fang Fang, Bayer Healthcare Pharmaceuticals ; Liping Huang, Bayer Healthcare Pharmaceuticals ; Minghua Shan, Bayer Healthcare Pharmaceuticals ; Xiaosha Zhang, Astellas Pharma U.S., Inc.
9:20 AM	Audit Strategies for Progressive-Free Survival — Meihua Wu, University of Michigan ; Kalyanee Kalyanee Appann, Novartis ; William Mietlowski, Novartis ; Yong Zhang, Novartis ; Can Cai, Novartis ; Paramita Saha, Novartis
9:35 AM	A Bayesian Approach in Assessing Surrogacy of Clinical Trial Endpoints — Manuela Buzoianu, PhD, FDA ; Shengyan Hong, MedImmune
9:50 AM	Semi-Mechanistic Modeling of the Dependence Structure Between Progression-Free Survival and Overall Survival — Dominik Heinzmann, Roche
10:05 AM	Competing Risk Analysis of PFS Considering Patients Who Switch Therapy Prior to Progression — Lixia Jiao, Sanofi Aventis

2012 JSM Online Program Home

For information, contact jsm@amstat.org or phone (888) 231-3473.

If you have questions about the Continuing Education program, please contact the Education Department.